Oncquest has evolved into a reference laboratory in the field of oncology, and more recently into a multi-platform Pathology Service provider with a core focus on Molecular, Haematology & Surgical Pathology Services, says Dr Ravi Gaur, Chief Operating Officer, Oncquest Laboratories Ltd., in conversation with Elets News Network (ENN).
Q Oncquest, India’s leading super specialised laboratory network, which is today known for its excellence in molecular and clinical diagnostic. Tell us briefly about the journey.
Oncquest Laboratories is India’ s most leading molecular diagnostic service provider with special focus on molecular oncology for almost 17 years. Our beginning as a research-focussed entity in 2001 has had a significant impact on the way we have evolved and progressed. Starting with a thenadvanced technology platform of multiplex PCR, we later added Next Gen Sequencing, digital droplet PCR, advanced surgical pathology including Immuno-histochemistry, Flow-Cytometry, FISH, Haematology, Cytogenetics and much more in our portfolio.
We are a technology and skill driven laboratory and our quest to perform and excel, makes us stand out amongst strong competitors. Our hunger for technology will never end.
From its first avatar as an R&D focused entity, Oncquest has evolved into a reference laboratory in the field of oncology, and more recently into a multi-platform Pathology Service provider with a core focus on Molecular, Haematology &Surgical Pathology Services.
Oncquest accreditation by College of American Pathologists (CAP& NABL) offers a range of laboratory tests for understanding the molecular basis of malignant transformations of the cells. These tests are designed to provide diagnosis and prediction of disease progression and can be used to tailor treatment to the individual patient’s cancer. Oncquest utilises the experience and expertise of trained scientists and pathologist to provide clinicians with an incisive diagnosis to identify the disease process at the fine point of differentiation.
Q You provide world class facilities to your clients. Tell us about your services ‘specialised services’ and ‘general pathology’.
Oncquest offers one of the largest test portfolios especially in molecular oncology, in exploratory and end-point biomarkers, genomics, Haematology& Surgical pathology.
Our ‘specialised services’ cover over 1,500 advanced technologybased assays covering screening, final diagnosis, monitoring and prognosis. The capabilities include, real time and multiplex PCR, Gene Sequencing, Next Generation Sequencing (NGS), Cytogenetics, FISH-based assays, advanced Haematology and Flow cytometry, Immuno-histochemistry (IHC) and Surgical Pathology.
In general pathology space, we offer almost entire spectrum of biochemistry, immunology, hematology, clinical pathology and microbiology helping in clinical diagnosis, prevention, prediction, early diagnosis, monitoring, Hospital Lab Management& much more. Today, we have a state-of-the-art Molecular and Clinical Diagnostics Referral Laboratory, with a national footprint of over 36 laboratories, 200 collection centers and 1,300+ service associates across India and South East Asia.
Q What distinguishes you from others in terms of adoption of cutting-edge technology and quality of service?
We handle over 15,000 tests every day. We have a highly skilled team of doctors and scientists, trained in most advanced technology driven platforms. Our team is well integrated with clinicians and patients to provide final and correct diagnosis which can help the clinicians in designing personalised and target based therapy, early diagnosis and its recurrence.
Our majority of partnerships are in tertiary care or super specialised hospitals catering to oncology, gastroenterology, infertility, immunology, nephrology, cardiology, critical care ,infectious disease, preventive and wellness space .We bring proven international assays to India, validate them for India specific environment and make it affordable to Indian population.
Today, Oncquest is known as final opinion provided and more so for complicated cases. The pathology is all about guiding the clinicians in their diagnostic dilemma. I personally believe that all pathologists are clinical solution provider and they should keep themselves fully updated and work hand in hand with clinicians to provide themsolutions for better treatment outcome.
Q Shed some light on molecular tests which you have launched in Indian market recently.
Oncquest Laboratories has launched many new advanced assays and on high-end technology driven platforms for first time in India. With rapid advancement and availability of new technology many more new assays are now being offered.
Next Generation Sequencing (NGS) based assays for better and focused tumor profiling, Liquid biopsy for very early diagnosis of cancers, Minimal Residual Disease (MRD) in leukemia, Final diagnosis of cancers on tissue, FISH based assays, Bone marrows for Myeloma & blood cancers and cytogenetic testing for hematological malignancies are few of the recently launched tests.
Q Oncquest is pioneer in oncology and market leader in tests like BCR ABL and Minimal Residual Disease (MRD). Please elaborate about these tests.
Oncquest is India’s Largest Cancer Diagnostics Laboratory in South East Asia and market leader. Oncquest is pioneer in oncology and market leader in so many tests like BCR ABL and MRD. Over 60 per cent BCR/ ABL testing and 70 per cent MRDs (Minimal residual disease) testing in India is performed by us.
We have been continuously improving our TAT (Turnaround Time) and technical platform for the same. These advanced assays have helped researchers, clinicians and patients to understand molecular basis of cancer and plan more specific and successful target based therapies. BCR/ ABL Testing with International Scale Reporting helps in the diagnosis and monitoring of chronic myelogenous leukaemia (CML) and few , though rare acute lymphoblastic leukaemia (ALL).
We have been continuously improving our TAT (Turnaround Time) and technical platform for the same. These advanced assays have helped researchers, clinicians and patients to understand molecular basis of cancer and plan more specific and successful target based therapies.
BCR/ABL Testing with International Scale Reporting helps in the diagnosis and monitoring of chronic myelogenous leukaemia (CML) and few , though rare acute lymphoblastic leukaemia (ALL).
Both these cancers affect the mature blood cells and their precursors in the bone marrow; Chronic myelogenous leukaemia and certain types of acute lymphoblastic leukaemia are caused by the product of abnormal BCR-ABL gene fusions. Minimal residual Disease ( MRD) refers to the presence of leukemic cells below the threshold of detection by conventional morphology. MRD analysis aims at estimating total burden of leukemic cells during remission. It is helpful in identifying those patients whose outcome with conventional chemotherapy treatment is likely to be poor, patients with high risk and providing sensitive monitoring post treatment.
Oncquest is preferred for BCR/ ABL &MRD testing because of its quality parameters and highly skilled